February 16 2023 - 07:00AM
GlobeNewswire Inc.
Alert
Share On Facebook
NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.
AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory. The abstract describes the ability of multi-TAA AIM ACT T cells to work synergistically with BiTE therapy, revealing several important advantages over endogenous TAA nonspecific CD8 T cells + BiTE. The results show that BiTE potency, as measured by a reduction in tumor burden in vivo, is markedly increased in the presence of AIM T cells. Importantly, following withdrawal of BiTE therapy, recipients of the AIM ACT T cell combination remained tumor free or had a low tumor burden, while those that had received the bulk CD8+ T cell combination died within two weeks. This observation strongly suggests that AIM ACT T cells provide immunosurveillance following the withdrawal of the BiTE, a distinct advantage over bulk CD8+ T cells, which should contribute to the maintenance of remission.
“Our preclinical findings hold the promise that clinically, the AIM multi-TAA specific T cells can significantly enhance the activity of BiTEs over the current standard of care and also provide immunosurveillance, potentially helping extension and maintenance of remission in patients,” said Principal Investigator, Johannes Zakrzewski, M.D., Associate Member of the Center for Discovery and Innovation at Hackensack University Medical Center.
Abstract details:
Title: Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy
Lead Authors: Mark Batistick, Center for Discovery and Innovation, Hackensack Meridian Health
Abstract #:
Date/Time: 22061
February 16, 2023 at 5:45 pm ET (virtual poster presentation)
About NexImmune
NexImmune is a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities. NexImmune is focused on developing injectable AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology, autoimmune disorders and infectious diseases.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to managem
Recent NEXI News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/11/2024 07:12:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 07:10:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 11:58:48 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/11/2024 09:17:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:28:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 09:10:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:01:30 PM
- Konzernabschluss zum 31. März 2024 verabschiedet, kontinuierliches Wachstum und Ausweitung der EBITDA-Marge, Aktienrückkaufprogramm in Höhe von 500 Millionen Euro gestartet • Business Wire • 05/09/2024 04:39:00 PM
- Approbation des résultats financiers du groupe au 31 mars 2024, poursuite de la croissance et de l’augmentation de la marge de BAIIA, lancement d’un programme de rachat d’actions de 500 millions € • Business Wire • 05/09/2024 04:39:00 PM
- Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, € 500 Million Share Buy-Back Program Launched • Business Wire • 05/09/2024 06:00:00 AM
- Konzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen Euro • Business Wire • 03/07/2024 06:20:00 PM
- Approbation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’euros • Business Wire • 03/07/2024 05:33:00 PM
- Approvati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprie • Business Wire • 03/07/2024 06:31:00 AM
- Group Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back Program • Business Wire • 03/07/2024 06:30:00 AM
- NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/06/2024 09:42:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/06/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 10:10:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/05/2024 09:34:15 PM
- NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/02/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 06:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:17:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:43:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/18/2024 09:43:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:01:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 06:39:59 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM